Conference Proceedings

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmuniotheraphy

Jacob D Soumerai, Ai Ni, Mohamed Darif, Anil Londhe, Guan Xing, Yong Mun, Neil E Kay, Tait D Shanafelt, Kari G Chaffee, Richard R Furman, Peter Hillmen, Jeff Sharman, John F Seymour, Asher A Chanan-Khan, John C Byrd, Jeffrey A Jones, Lucille A Ferrante, Lyndah K Dreiling, Mehrdad Mobasher, Thomas Stark Show all

Blood | AMER SOC HEMATOLOGY | Published : 2018